PSMA Radiotherapy Before Prostate Cancer Surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a radioactive drug (PSMA-RLT) given before surgery for prostate cancer that has spread to a few spots. It aims to see if this treatment can stop the cancer from growing further.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your prostate cancer has spread to only a few spots (5 or fewer in bones, or 3 or fewer in lungs) seen on a special PSMA PET scan.
- You are generally up and about (ECOG 0 or 1) – meaning you can do daily activities without needing help.
- You are 75 years old or younger.
- You have never had hormone therapy (like Lupron, Zoladex, or similar) for your cancer.
- Your kidney function and blood cell counts are good enough to handle the treatment safely.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two radioactive drugs (177Lu-PSMA-617 and 225Ac-PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that has not spread far. The goal is to see which drug is better at shrinking the tumor and reducing the chance of cancer coming back.
This study tests a new radioactive drug (177Lu-PSMA-137) that targets a marker on prostate cancer cells called PSMA. It aims to see if this treatment is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments.
This trial tests whether adding a PSMA-targeted radioactive medicine (Lu-PSMA) to focused stereotactic radiation to a few prostate cancer spots works better than radiation alone. It may help people with limited, asymptomatic spread of prostate cancer by improving cancer control while carefully monitoring side effects.
This trial tests if a special PET scan using PSMA-1007 can find prostate cancer spread in men who have just been diagnosed with high-risk prostate cancer and plan to have surgery. The scan may help doctors better understand the cancer before removing the prostate and lymph nodes.
This trial is testing whether a special scan (PSMA PET/CT) before surgery can help doctors decide if you need to remove lymph nodes. It is for men with high-risk prostate cancer who are already planning to have robot-assisted prostate removal.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.